Suppliers and packagers for levonorgestrel

levonorgestrel

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Annora Pharma	LEVONORGESTREL	levonorgestrel	TABLET;ORAL	219102	ANDA	Camber Consumer Care Inc	69230-333-32	1 BLISTER PACK in 1 CARTON (69230-333-32) / 1 TABLET in 1 BLISTER PACK	2025-09-30
Annora Pharma	LEVONORGESTREL	levonorgestrel	TABLET;ORAL	219102	ANDA	Camber Consumer Care Inc	69230-333-33	2 BLISTER PACK in 1 CARTON (69230-333-33) / 1 TABLET in 1 BLISTER PACK	2025-09-30
Annora Pharma	LEVONORGESTREL	levonorgestrel	TABLET;ORAL	219102	ANDA	Camber Consumer Care Inc	69230-333-34	5 BLISTER PACK in 1 CARTON (69230-333-34) / 1 TABLET in 1 BLISTER PACK	2025-09-30
Glenmark Pharms Ltd	LEVONORGESTREL	levonorgestrel	TABLET;ORAL	207044	ANDA	GLENMARK THERAPEUTICS INC., USA	72657-108-12	1 BLISTER PACK in 1 CARTON (72657-108-12) / 1 TABLET in 1 BLISTER PACK	2022-07-29
Glenmark Pharms Ltd	LEVONORGESTREL	levonorgestrel	TABLET;ORAL	207044	ANDA	GLENMARK THERAPEUTICS INC., USA	72657-123-11	1 BLISTER PACK in 1 CARTON (72657-123-11) / 1 TABLET in 1 BLISTER PACK	2023-02-09
Glenmark Pharms Ltd	LEVONORGESTREL	levonorgestrel	TABLET;ORAL	207044	ANDA	YYBA Corp	73581-217-01	1 BLISTER PACK in 1 CARTON (73581-217-01) / 1 TABLET in 1 BLISTER PACK	2026-03-01

Levonorgestrel Suppliers: Key Manufacturers and Market Dynamics

Last updated: February 19, 2026

This analysis identifies key suppliers of levonorgestrel active pharmaceutical ingredient (API) and examines market trends impacting its procurement. Manufacturers in China and India dominate global production, driven by cost efficiencies and established chemical synthesis capabilities. Supply chain resilience, regulatory compliance, and price volatility are critical considerations for pharmaceutical companies.

What are the primary global suppliers of Levonorgestrel API?

The global supply of levonorgestrel API is concentrated among a few key manufacturers, primarily located in Asia. These companies leverage large-scale production facilities and specialized expertise in steroid synthesis.

• China: Several Chinese manufacturers are significant producers of levonorgestrel. These include:
  • Hubei Biocause Pharmaceutical Co., Ltd.: A major player with substantial production capacity for steroid hormones.
  • Zhejiang Huahai Pharmaceutical Co., Ltd.: Known for its broad API portfolio, including steroidal compounds.
  • Jiangsu Haosen Pharmaceutical Co., Ltd.: Another established Chinese API producer with a focus on complex organic synthesis.
• India: Indian pharmaceutical companies also play a vital role in the levonorgestrel supply chain. Key suppliers include:
  • Sun Pharmaceutical Industries Ltd.: A global pharmaceutical giant with significant API manufacturing capabilities.
  • Divi's Laboratories Limited: A prominent API and intermediate manufacturer with advanced synthesis technology.
  • Laurus Labs Limited: Increasingly recognized for its API production, including complex molecules.
• Europe: While less dominant in bulk API production compared to Asia, some European companies may offer specialized or niche levonorgestrel products or intermediates.

The production of levonorgestrel involves complex multi-step chemical synthesis, often starting from diosgenin or other steroidal precursors. The efficiency and cost-effectiveness of these synthesis routes are critical factors for API manufacturers.

What are the key manufacturing processes and raw material dependencies for Levonorgestrel?

Levonorgestrel, a synthetic progestin, is manufactured through complex organic synthesis pathways. The primary raw materials and intermediates are derived from steroidal compounds, historically sourced from plants.

• Steroidal Precursors: The synthesis typically begins with steroidal sapogenins, such as diosgenin, extracted from plants like yams (Dioscorea species) or soy. These natural sources are processed to yield key intermediates like dehydroepiandrosterone (DHEA) or androstenedione.
  • Diosgenin Extraction: This involves hydrolysis of saponins found in plant sterols. The availability and cost of these plant-derived raw materials can fluctuate based on agricultural yields and geopolitical factors.
  • Intermediate Synthesis: Diosgenin is then converted through a series of chemical reactions into intermediates suitable for levonorgestrel synthesis.
• Synthetic Pathways: Multiple synthetic routes exist for levonorgestrel, each involving several chemical transformations. A common pathway involves the conversion of a suitable C19 steroid intermediate into a C18 steroid with the characteristic ethinyl group at the 17α position and the characteristic methyl group at the 13 position.
  • Key Reactions: These typically include oxidation, reduction, Grignard reactions (for ethinylation), and stereoselective transformations to achieve the desired configuration.
  • Catalysts and Reagents: The processes require a range of specialized chemical reagents and catalysts, the procurement of which is crucial for continuous production.
• Raw Material Sourcing: Manufacturers depend on reliable suppliers of these steroidal precursors and essential chemical reagents. The supply chain for these upstream materials can be as critical as the API manufacturing itself.
  • Geographic Concentration: Sourcing of steroidal precursors is often concentrated in specific regions, creating potential supply chain vulnerabilities.
  • Quality Control: Stringent quality control measures are essential at each stage of synthesis to ensure the purity and efficacy of the final API.

The complexity of the synthesis means that manufacturers must possess advanced chemical engineering capabilities and robust supply chain management for raw materials.

What is the regulatory landscape governing Levonorgestrel API manufacturing and supply?

The manufacturing and supply of levonorgestrel API are subject to stringent regulatory oversight by health authorities worldwide. Compliance is mandatory for market access and product approval.

• Good Manufacturing Practices (GMP): All API manufacturers must adhere to GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO).
  • Facility Inspections: Manufacturing sites undergo regular inspections to ensure compliance with GMP standards, covering aspects like quality management systems, personnel, building and facilities, equipment, documentation, and production and process controls.
  • Quality Management Systems: Robust quality management systems are required to ensure the consistent production of API meeting predefined specifications.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers typically submit DMFs (in the U.S.) or ASMFs (in Europe) to regulatory authorities. These confidential documents provide detailed information about the manufacturing process, facilities, quality control, and stability of the API.
  • Confidentiality: These filings allow regulatory agencies to review the API information without disclosing proprietary manufacturing details to the drug product applicant.
  • Reference: Pharmaceutical companies developing finished drug products reference these DMFs/ASMFs in their marketing authorization applications.
• Pharmacopoeial Standards: Levonorgestrel API must meet the quality standards defined in major pharmacopoeias, including:
  • United States Pharmacopeia (USP): Sets standards for identity, strength, quality, and purity.
  • European Pharmacopoeia (Ph. Eur.): Similar to USP, providing harmonized standards for Europe.
  • Japanese Pharmacopoeia (JP): Standards for the Japanese market.
  • International Harmonization: Efforts are ongoing to harmonize pharmacopoeial requirements globally.
• Import/Export Regulations: International trade of levonorgestrel API is subject to import and export regulations, including country-specific registration requirements and potential restrictions.
• Inspections by Finished Product Manufacturers: Pharmaceutical companies are increasingly conducting their own audits and inspections of API suppliers to ensure supply chain integrity and quality assurance, often supplementing regulatory inspections.

Adherence to these regulations is critical for API suppliers to remain competitive and to ensure patient safety. Non-compliance can lead to product recalls, import alerts, and significant financial penalties.

What are the market dynamics influencing Levonorgestrel API pricing and availability?

Several factors contribute to the pricing and availability of levonorgestrel API, creating a dynamic market environment for purchasers.

• Supply and Demand: Like any commodity, the fundamental balance of supply and demand significantly impacts pricing. High demand for finished products, particularly contraceptives and hormone replacement therapies, can drive up API prices. Conversely, overcapacity or reduced demand can lead to price erosion.
  • Demand Drivers: Increased global access to reproductive health services and an aging population requiring hormone therapy are key demand drivers.
  • Supply Consolidation: Consolidation among API manufacturers can reduce competitive pressure and potentially lead to price increases.
• Raw Material Costs: Fluctuations in the cost of steroidal precursors and other essential chemical inputs directly affect manufacturing costs and, subsequently, API pricing.
  • Agricultural Yields: Dependency on plant-derived precursors makes the supply chain susceptible to agricultural factors, including weather patterns and crop disease.
  • Geopolitical Instability: Disruptions in regions where key raw materials are sourced can lead to price volatility.
• Regulatory Compliance Costs: The significant investment required for maintaining GMP compliance, conducting validation studies, and undergoing regulatory inspections adds to the overall cost of API production.
  • New Regulations: Implementation of stricter environmental or quality regulations can increase operational expenses for manufacturers.
• Competition Among Suppliers: The competitive landscape, particularly with major suppliers in China and India, exerts downward pressure on prices. However, established relationships, quality certifications, and reliability can allow some suppliers to command premium pricing.
  • Asian Dominance: The cost advantages offered by manufacturers in China and India continue to shape global pricing benchmarks.
• Intellectual Property: While the patent protection for levonorgestrel itself has long expired, process patents related to novel synthesis routes or improved purification methods could influence the competitive landscape and pricing for specific suppliers.
• Geopolitical and Trade Policies: Tariffs, trade wars, and changing international trade agreements can impact the cost of importing API or raw materials, affecting final pricing.
  • Supply Chain Diversification: Companies are increasingly looking to diversify their supplier base to mitigate risks associated with geopolitical instability and trade disputes.
• Quality and Reliability: Pharmaceutical companies often prioritize suppliers with a proven track record of quality, regulatory compliance, and supply chain reliability, even if it means a slightly higher price.

These factors interact to create a complex pricing structure and can influence the strategic decisions of pharmaceutical companies regarding API sourcing.

What are the key considerations for pharmaceutical companies when selecting Levonorgestrel API suppliers?

Selecting the right levonorgestrel API supplier is critical for ensuring product quality, regulatory compliance, and supply chain security. Pharmaceutical companies must conduct thorough due diligence.

• Regulatory Compliance and Quality Assurance:
  • GMP Certification: Verification of current GMP certifications from relevant authorities (FDA, EMA, WHO).
  • Inspection History: Review of past regulatory inspection reports and any issued warning letters or import alerts.
  • Quality Management System (QMS): Assessment of the robustness of the supplier's QMS, including change control, deviation management, and CAPA processes.
  • Pharmacopoeial Compliance: Confirmation that the API meets USP, Ph. Eur., or other required pharmacopoeial standards.
  • DMF/ASMF Status: Availability and acceptance of the supplier's DMF or ASMF by target regulatory agencies.
• Manufacturing Capabilities and Capacity:
  • Production Scale: Ability to meet current and projected future demand volumes.
  • Process Control and Validation: Evidence of well-controlled and validated manufacturing processes.
  • Technical Expertise: Demonstrated expertise in complex steroid synthesis.
  • Facility Modernization: Assessment of the supplier's investment in modern manufacturing technology and infrastructure.
• Supply Chain Reliability and Risk Management:
  • Raw Material Sourcing: Transparency into the supplier's raw material sourcing strategy and the reliability of their upstream supply chain.
  • Business Continuity Planning: Evaluation of the supplier's plans for disaster recovery and business continuity.
  • Geographic Diversification: Consideration of suppliers with manufacturing sites in multiple locations to mitigate regional risks.
  • Lead Times and Delivery Performance: Assessment of historical on-time delivery rates and acceptable lead times.
• Cost and Commercial Terms:
  • Pricing Transparency: Clear and competitive pricing structures.
  • Payment Terms: Favorable payment terms.
  • Contractual Agreements: Robust supply agreements that clearly define responsibilities, quality standards, and pricing adjustments.
  • Long-Term Partnership Potential: Willingness and ability of the supplier to enter into long-term supply agreements.
• Auditing and Support:
  • Willingness to be Audited: Supplier's openness to on-site audits by the pharmaceutical company.
  • Technical Support: Availability of technical expertise for troubleshooting and process optimization.
  • Regulatory Support: Proactive communication and support regarding regulatory changes or inquiries.

A comprehensive supplier qualification program, including rigorous audits and ongoing performance monitoring, is essential for mitigating risks associated with API procurement.

What are the emerging trends and future outlook for Levonorgestrel API supply?

The levonorgestrel API market is evolving, influenced by technological advancements, global health initiatives, and shifts in manufacturing and regulatory environments.

• Increased Demand for Contraceptives: Global efforts to expand access to family planning services, particularly in low- and middle-income countries, continue to drive demand for levonorgestrel-based contraceptives (e.g., implants, IUDs, emergency contraception).
  • Public Health Programs: International health organizations and national governments are investing in programs that increase the use of long-acting reversible contraceptives (LARCs), many of which utilize levonorgestrel.
• Technological Advancements in Synthesis: Ongoing research focuses on developing more efficient, cost-effective, and environmentally friendly synthesis routes for levonorgestrel.
  • Green Chemistry: Adoption of greener solvents, catalysts, and waste reduction techniques in API manufacturing processes.
  • Continuous Manufacturing: Exploration of continuous manufacturing technologies for API production, potentially leading to improved efficiency and consistency.
• Supply Chain Resilience and Diversification: The COVID-19 pandemic highlighted vulnerabilities in global supply chains. Pharmaceutical companies are increasingly seeking to diversify their supplier base and secure multiple sources of critical APIs like levonorgestrel.
  • Reshoring/Nearshoring: Some companies may explore bringing API manufacturing closer to their finished product sites to reduce lead times and geopolitical risks, though cost remains a significant factor.
• Evolving Regulatory Expectations: Regulatory agencies worldwide are continuously updating their expectations regarding API quality, data integrity, and supply chain transparency.
  • Data Integrity: Increased scrutiny on data integrity across all stages of API manufacturing and testing.
  • Traceability: Enhanced requirements for traceability of raw materials and intermediates.
• Emergence of New Markets and Applications: While well-established, research may uncover new therapeutic applications or improved delivery methods for levonorgestrel, potentially influencing future demand.
  • Hormone Therapy Innovation: Continued development in hormone replacement therapy and gynecological treatments may create new market segments.
• Sustainability Initiatives: Growing pressure from investors and consumers for more sustainable manufacturing practices will likely influence API production.
  • Environmental Impact: Focus on reducing the environmental footprint of chemical synthesis processes.

The future outlook for levonorgestrel API supply suggests continued strong demand, driven by its essential role in reproductive health, coupled with an increasing emphasis on supply chain robustness, technological innovation, and sustainable manufacturing practices.

Key Takeaways

• Global levonorgestrel API production is dominated by manufacturers in China and India, leveraging cost efficiencies in complex steroid synthesis.
• The manufacturing process relies on steroidal precursors, often plant-derived, making the supply chain susceptible to agricultural and geopolitical factors.
• Stringent regulatory requirements, including GMP and pharmacopoeial standards, are paramount for API suppliers and necessitate significant ongoing investment.
• Market pricing and availability are influenced by supply-demand dynamics, raw material costs, regulatory compliance expenses, and competitive pressures.
• Pharmaceutical companies must prioritize regulatory compliance, manufacturing capacity, supply chain reliability, and cost when selecting API suppliers.
• Future trends indicate sustained demand, a focus on supply chain resilience through diversification, advancements in greener synthesis technologies, and evolving regulatory expectations.

Frequently Asked Questions

1. What are the typical lead times for ordering Levonorgestrel API from major suppliers?

Typical lead times can range from 8 to 16 weeks, depending on the supplier's production schedule, existing inventory, and the quantity ordered. For significant orders or custom manufacturing requirements, lead times can extend.

2. How can pharmaceutical companies mitigate the risk of supply chain disruptions for Levonorgestrel API?

Mitigation strategies include qualifying multiple suppliers in different geographic regions, maintaining strategic inventory levels, conducting regular supplier audits, and developing strong contractual agreements that address supply continuity.

3. Are there any critical quality attributes for Levonorgestrel API that purchasers should pay close attention to?

Key quality attributes include assay (potency), purity (specifically related to known impurities and stereoisomers), residual solvents, heavy metals, and particle size distribution, as these can impact the performance and stability of the finished drug product.

4. What is the typical shelf-life of Levonorgestrel API when stored under recommended conditions?

Levonorgestrel API, when stored under controlled conditions (typically protected from light and moisture, and at controlled room temperature), generally has a shelf-life of 2 to 5 years, as determined by stability studies submitted in regulatory filings.

5. How do patent expiries affect the availability and pricing of Levonorgestrel API?

The primary patents for levonorgestrel itself have expired, leading to a generic API market. This expiry has facilitated the entry of multiple manufacturers, intensifying competition and generally driving down API prices, while process patents for specific manufacturing methods may still exist for certain suppliers.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Inspections, Compliance, Enforcement, and Criminal Investigations. Retrieved from [FDA Website] (Note: Actual URL would be specific to FDA inspection guidance)

[2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from [EMA Website] (Note: Actual URL would be specific to EMA GMP guidance)

[3] United States Pharmacopeia. (n.d.). Monograph Search. Retrieved from [USP Website] (Note: Access to specific monograph requires subscription)

[4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Active Substances. Retrieved from [EDQM Website] (Note: Actual URL would be specific to EDQM ASMF information)